APMD
Apnimed, Inc.☾After Hours 0.00 (0.00%)Nov 4, 7:59 PM ET
At close $15.28 · +0.22 (+1.43%)
About APMD
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).
Sign up free to see this.
Analysts
All ›Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
Sentiment
No sentiment yet
Votes and Bull · Bear posts, 24h. At least 5 are needed.
How do you feel about APMD?
Board · 0 threads
Open board ›No threads yet
Community opinions, not advice. Posts with a target get a receipt. How receipts work ›